2022
Age- and sex-specific associations between risk scores for schizophrenia and self-reported health in the general population
Paquin V, Pries L, ten Have M, Bak M, Gunther N, de Graaf R, van Dorsselaer S, Lin B, van Eijk K, Kenis G, Richards A, O’Donovan M, Luykx J, Rutten B, van Os J, Shah J, Guloksuz S. Age- and sex-specific associations between risk scores for schizophrenia and self-reported health in the general population. Social Psychiatry And Psychiatric Epidemiology 2022, 58: 43-52. PMID: 35913550, PMCID: PMC9845157, DOI: 10.1007/s00127-022-02346-3.Peer-Reviewed Original ResearchConceptsSex-specific associationsSelf-reported healthPRS-SCZES-SCZPhysical healthGeneral populationNetherlands Mental Health SurveyIncidence Study-2Mental Health SurveyHealth SurveyRisk scoreAge 65Common genetic variantsHealth correlatesAge 18Poor healthOlder individualsMental healthPolygenic riskLinear mixed modelsAgeSexExposome scoreHealthAssociation
2020
Predictive Performance of Exposome Score for Schizophrenia in the General Population
Pries L, Erzin G, van Os J, Have M, de Graaf R, van Dorsselaer S, Bak M, Rutten B, Guloksuz S. Predictive Performance of Exposome Score for Schizophrenia in the General Population. Schizophrenia Bulletin 2020, 47: 277-283. PMID: 33215211, PMCID: PMC7965069, DOI: 10.1093/schbul/sbaa170.Peer-Reviewed Original ResearchConceptsES-SCZOptimal cut pointGeneral populationPopulation cohortGeneral population cohortCut pointsExposome scoreSchizophrenia spectrum disordersMeta-analytical estimatesClinical outcomesRisk strataRisk stratificationMulticausal etiologyMedical outcomesPsychiatric diagnosisBipolar disorderSchizophrenia diagnosisExposure scoreSuicide planSum scoreGene-environment interaction studiesSchizophreniaRisk predictionCharacteristic curveScoresDo Current Measures of Polygenic Risk for Mental Disorders Contribute to Population Variance in Mental Health?
Marsman A, Pries L, Have M, de Graaf R, van Dorsselaer S, Bak M, Kenis G, Lin B, Luykx J, Rutten B, Guloksuz S, van Os J. Do Current Measures of Polygenic Risk for Mental Disorders Contribute to Population Variance in Mental Health? Schizophrenia Bulletin 2020, 46: 1353-1362. PMID: 33259628, PMCID: PMC7707067, DOI: 10.1093/schbul/sbaa086.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAdverse Childhood ExperiencesAgedFamilyFemaleGenetic Predisposition to DiseaseHealth SurveysHumansLife Change EventsLongitudinal StudiesMaleMarijuana UseMiddle AgedMultifactorial InheritanceNetherlandsPsychotic DisordersSchizophreniaSocioeconomic FactorsUrban PopulationYoung AdultConceptsPolygenic risk scoresSchizophrenia polygenic risk scoresMental healthFamily historyNetherlands Mental Health SurveyPopulation-based studyPolygenic riskChildhood traumaMental Health SurveyMental health changesEnvironmental risk factorsGeneral mental healthPopulation mental healthGeneral population sampleSomatic painRisk factorsHealth SurveyRisk scorePRS-SZBipolar disorderEpidemiological settingsMental disordersHealth changesAttributable variationPain
2015
The impact of electroconvulsive therapy on the tryptophan–kynurenine metabolic pathway
Guloksuz S, Arts B, Walter S, Drukker M, Rodriguez L, Myint A, Schwarz M, Ponds R, van Os J, Kenis G, Rutten B. The impact of electroconvulsive therapy on the tryptophan–kynurenine metabolic pathway. Brain Behavior And Immunity 2015, 48: 48-52. PMID: 25765557, DOI: 10.1016/j.bbi.2015.02.029.Peer-Reviewed Original ResearchConceptsTrp-Kyn pathwayHamilton Depression Rating Scale-17 itemsElectroconvulsive therapyBeck Depression InventoryMechanism of actionKynurenic acidTrp-KynKyn/Trp ratioKYNA/KYN ratioTryptophan-kynurenine metabolic pathwayLast ECT sessionBilateral electroconvulsive therapyKyn/TrpTreatment of depressionMultilevel linear regression analysesKYN metabolitesECT sessionsAntidepressant effectsECT responseBipolar depressionECT treatmentTrp ratioNeuroprotective propertiesKynurenine pathwayNeurotoxic processes
2013
Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial
Tek C, Guloksuz S, Srihari VH, Reutenauer EL. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC Psychiatry 2013, 13: 176. PMID: 23805859, PMCID: PMC3702521, DOI: 10.1186/1471-244x-13-176.Peer-Reviewed Original ResearchConceptsSevere mental illnessEfficacy of naltrexoneWeight gainOutcome measurementsHealth problemsMental illnessGreater New Haven areaTumor necrosis factor alphaWeight lossCurrent available medicationsPlacebo-controlled trialHigh-sensitivity CRPOpioid receptor antagonistSecondary outcome measuresSerum lipid profilePrimary outcome measurementBody mass indexD2 receptor blockadeEffects of naltrexoneNovel pharmacological optionsNecrosis factor alphaDoses of naltrexoneMajor health problemRates of obesitySignificant weight lossMetabolic syndrome prevalence in different affective temperament profiles in bipolar-I disorder
Altinbas K, Guloksuz S, Oral E. Metabolic syndrome prevalence in different affective temperament profiles in bipolar-I disorder. Brazilian Journal Of Psychiatry 2013, 35: 131-135. PMID: 23904017, DOI: 10.1590/1516-4446-2011-0746.Peer-Reviewed Original ResearchConceptsMetabolic syndrome prevalenceDevelopment of MetSInternational Diabetes FederationMetabolic syndrome markersMood Disorders UnitSan Diego-Autoquestionnaire versionProportion of MetSDepressive temperament scoresAffective temperament profilesMetS prevalenceDiabetes FederationSyndrome prevalenceDisorders unitBipolar patientsBrain structuresSocioeconomic statusTemperament EvaluationPatientsMetSPrevalenceTemperament profilesTemperament scoresTemperamental profilesMetS.